Rigel Pharmaceuticals Completes Transfer Of GAVRETO New Drug Application; Will Be Available In The U.S. Beginning June 27, 2024
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals has completed the transfer of the New Drug Application for GAVRETO, a treatment for certain types of cancer. GAVRETO will be available in the U.S. starting June 27, 2024.
June 24, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rigel Pharmaceuticals has completed the transfer of the NDA for GAVRETO, a treatment for specific types of cancer. The drug will be available in the U.S. starting June 27, 2024.
The completion of the NDA transfer and the upcoming availability of GAVRETO in the U.S. is a significant milestone for Rigel Pharmaceuticals. This development is likely to positively impact the company's stock price in the short term as it expands its product portfolio and potential revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100